

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

INSIDE INFORMATION
LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE
FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION
BY THE COMPANY

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated December 15, 2025 and May 8, 2026 (the “**Announcements**”) in relation to the proposed implementation of H Share Full Circulation program by the Company and the issuance of Filing Notice by the CSRC for the H Share Full Circulation and proposed implementation of H Share Full Circulation by the Company. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL GRANTED BY THE HONG KONG STOCK EXCHANGE

The Board is pleased to announce that the Company has received the approval granted by the Stock Exchange on May 14, 2026 for the listing of, and permission to deal in, 44,391,598 H Shares (the “**Converted H Shares**”).

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve a total of 23 participating shareholders (the “**Participating Shareholders**”) holding an aggregate of 44,391,598 Unlisted Shares. The shareholdings of the Participating Shareholders in the Company’s Converted H Shares upon completion of the Conversion and Listing are set out as follows:

No.	Name of participating Shareholders	Number of Unlisted Shares converted into H Shares	Approximate percentage of the total issued shares of the Company (including treasury shares) upon completion of the Conversion and Listing ^{Note}
1	Kang Xiaoqiang	3,937,308	1.98%
2	Lai Shoupeng	3,192,410	1.61%
3	Nanjing Lizhi Management & Consulting Center (Limited Partnership) (南京禮至企業管理諮詢中心 (有限合夥))	6,422,721	3.23%
4	Nanjing Ennovation Raylight Venture Capital Partnership (Limited Partnership) (南京恩然瑞光創業投資合夥企業 (有限合夥))	2,950,645	1.48%
5	Nanjing Qiruiyoukang Venture Capital Partnership (Limited Partnership) (南京其瑞佑康創業投資合夥企業 (有限合夥))	1,526,891	0.77%
6	Ningbo Lan Hui Investment Management Partnership Enterprise (Limited Partnership) (寧波攬慧投資管理合夥企業 (有限合夥))	610,755	0.31%
7	Shenzhen Capital Group Co., Ltd. (深圳市創新投資集團有限公司)	832,648	0.42%
8	Shenzhen Hongtu Medical Health Industry Equity Investment Fund Partnership (L.P.) (深圳紅土醫療健康產業股權投資基金合夥企業 (有限合夥))	832,648	0.42%
9	Nanjing Enjie Venture Capital Partnership (Limited Partnership) (南京恩捷創業投資合夥企業 (有限合夥))	666,118	0.33%
10	LeadsBio Limited	463,936	0.23%
11	LeadsTech Limited	960,002	0.48%
12	Hankang Small and Medium Enterprises Development Fund (Weifang) Partnership Enterprise (Limited Partnership) (漢康中小企業發展基金 (濰坊) 合夥企業 (有限合夥))	1,683,194	0.85%
13	Loyal Valley Capital Advantage Fund III LP	9,991,770	5.02%
14	Shanghai Leyong Investment Partnership Enterprise (Limited Partnership) (上海樂永投資合夥企業 (有限合夥))	1,998,356	1.00%
15	Anhui Kunlu Venture Capital Partnership (Limited Partnership) (安徽昆路創業投資合夥企業 (有限合夥))	1,350,000	0.68%
16	Xinyu Shangxuan Equity Investment Partnership (Limited Partnership) (新余上宣股權投資合夥企業 (有限合夥))	500,000	0.25%

No.	Name of participating Shareholders	Number of Unlisted Shares converted into H Shares	Approximate percentage of the total issued shares of the Company (including treasury shares) upon completion of the Conversion and Listing ^{Note}
17	Ningbo Huaige Ruixin Venture Capital Partnership Enterprise (Limited Partnership) (寧波懷格銳信創業投資合夥企業 (有限合夥)) (formerly known as Jingning Huaige Ruixin Venture Investment Partnership Enterprise (Limited Partnership) (景寧懷格瑞信創業投資合夥企業 (有限合夥)))	832,648	0.42%
18	Nanjing Ennovation Chengfeng Entrepreneurship Investment Partnership (Limited Partnership) (南京恩然呈豐創業投資合夥企業 (有限合夥))	937,500	0.47%
19	Intellective Biologics (Suzhou) Limited (智享生物 (蘇州) 股份有限公司)	1,150,000	0.58%
20	Chengdu Huaige Guosheng Venture Investment Partnership (Limited Partnership) (成都懷格國生創業投資合夥企業 (有限合夥))	684,016	0.34%
21	Nanjing Jiakang Ruizhen Venture Investment Partnership (Limited Partnership) (南京佳康瑞臻創業投資合夥企業 (有限合夥))	684,016	0.34%
22	Shanghai Jishi Lemei Private Equity Investment Fund Partnership Enterprise (Limited Partnership) (上海濟世樂美私募投資基金合夥企業 (有限合夥))	684,016	0.34%
23	Guangzhou Kaide Phase I Biopharmaceutical Industry Investment Fund Partnership (Limited Partnership) (廣州凱得一期生物醫藥產業投資基金合夥企業 (有限合夥))	1,500,000	0.75%
Total		44,391,598	22.32%

Note:

Any discrepancies in this table between the total and sums of amounts are due to rounding.

The shareholding structure of the Company as at the date of this announcement and upon completion of the Conversion and Listing is set out as follows:

Type of shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	Number of shares	Approximate percentage of total issued shares of the Company	Number of shares	Approximate percentage of total issued shares of the Company
Unlisted Shares	45,613,109	22.93%	1,221,511	0.61%
H Shares	153,278,691	77.07%	197,670,289	99.39%
Total	198,891,800	100.00%	198,891,800	100.00%

The Company will complete the relevant conversion and trading procedures in respect of the Converted H Shares. The Company will make further announcement(s) on the progress of the H Share Full Circulation in accordance with the requirements of the Inside Information Provisions and/or the Listing Rules in due course.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
 南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
 Chief Executive Officer*

Nanjing, PRC, May 14, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng and Dr. Chen Renhai as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.